Incyte Q3 2024 revenues up 24% to $1.14B; Jakafi guidance raised

INCYTE CORP

2024-Q3 EPS reported -$0.80 revenue$3,062,519,000

Total revenues $1.138B (+24% YoY); Jakafi net revenue $741M (+16%); Opzelura $139M (+52%).
GAAP diluted EPS $0.54 vs $0.76 YoY; Non-GAAP diluted EPS $1.07 vs $1.10.
Jakafi 2024 guidance raised to $2.74-2.77B; Other Heme/Onco guidance reduced to $310-320M.
FDA approved Niktimvo (axatilimab) for chronic GVHD; sNDA filed for ruxolitinib cream in pediatric AD.
Phase 3 retifanlimab in SCAC and tafasitamab in FL met endpoints; sBLAs planned by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.